STOCK TITAN

Hoth Therapeutics Inc - HOTH STOCK NEWS

Welcome to our dedicated news page for Hoth Therapeutics (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hoth Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hoth Therapeutics's position in the market.

Rhea-AI Summary
Hoth Therapeutics, Inc. announces continued collaboration with Venable, LLP to enhance intellectual property protection for its life-changing therapeutics. Venable, a top law firm, will provide strategic counsel to safeguard Hoth's research and development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (HOTH) announces that its HT-KIT has received FDA Orphan Drug Status and continues to show positive study results in treating mast cell-derived cancers. The company has completed bioanalytical method development with Altasciences for a key study of mouse blood and plasma analysis from samples collected in sponsored scientific research at NC State University. The upcoming study will determine the amount of HT-KIT in the blood stream post dosing, aiding in the preclinical development process.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (HOTH) CEO to attend BIO CEO and Investor Conference in New York, NY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
Rhea-AI Summary
Hoth Therapeutics, Inc. (HOTH) has received FDA clearance for protocol amendments to its ongoing clinical trial for HT-001, a potential treatment for cancer patients undergoing treatment of skin toxicities associated with EGFRI. The trial aims to evaluate the efficacy, safety, and tolerability of HT-001 for treatment of EGFRI-induced skin toxicity. The study will be conducted in 2 parallel cohorts and aims to determine the minimum efficacious dose strength(s) for further investigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
clinical trial fda approval
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001, a Phase 2a clinical trial for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). The trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001. The company's CEO, Robb Knie, expressed optimism about the trial's potential to bring hope to cancer patients suffering from skin toxicities associated with EGFRi treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.26%
Tags
clinical trial
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT targets the proto-oncogene cKIT and has Orphan Drug Designation from the FDA. The company also completed its Pre-IND meeting with FDA and plans to use the GLP drug substance in its upcoming pre-clinical studies required for its investigational new drug (IND) submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
none
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) successfully completed a pre-IND meeting with the FDA for its HT-KIT therapeutic, targeting the proto-oncogene cKIT. The drug already has Orphan Drug Designation and is indicated for adult patients with AdvSM. The FDA's positive feedback allows Hoth to advance its IND-enabling activities as planned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
Rhea-AI Summary
Hoth Therapeutics, Inc. (NASDAQ: HOTH) to Present at NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
conferences acquisition
-
Rhea-AI Summary
Hoth Therapeutics announces new subsidiary to screen for rare disease therapeutics using AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
AI
Rhea-AI Summary
Hoth Therapeutics receives Pre-IND meeting approval from FDA for HT-KIT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
Hoth Therapeutics Inc

Nasdaq:HOTH

HOTH Rankings

HOTH Stock Data

5.82M
4.08M
0.93%
7.07%
1.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
New York

About HOTH

hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio